Risk Factors for Homologous Blood Transfusion and Impact of Cell Saver Use in Pediatric Scoliosis Surgery: A Retrospective Monocentric Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Proportion of patients requiring perioperative homologous Red Blood Cell (RBC) transfusion
研究概览
简要总结
Spine surgery for scoliosis correction in pediatric patients is a major procedure associated with a high risk of perioperative blood loss. Homologous blood transfusion carries inherent risks, including immunological reactions, infections, and increased healthcare costs. Identifying high-risk patients is crucial to optimize blood conservation strategies. This retrospective study aims to identify preoperative and intraoperative risk factors associated with homologous red blood cell (RBC) transfusion and to evaluate the quantitative impact of Cell Saver volume reinfusion on reducing homologous transfusion requirements.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- — 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient aged under 18 years (< 18 years old).
- •Programmed surgical correction for scoliosis (including idiopathic, neuromuscular, and congenital etiologies).
- •Instrumented surgery involving posterior spinal arthrodesis.
排除标准
- •Revision spine surgeries.
- •Known constitutional hemostasis disorders.
- •Non-orthopedic spine surgeries.
- •Missing core clinical or transfusion data.
研究组 & 干预措施
Pediatric Scoliosis Cohort
Pediatric patients under 18 years old who underwent posterior instrumented spinal fusion for scoliosis correction (idiopathic, neuromuscular, or congenital) between April 2023 and March 2026. This single cohort is evaluated retrospectively to identify risk factors for homologous blood transfusion and to assess the impact of intraoperative Cell Saver use
干预措施: posterior Instrumented Spinal Fusion (Procedure)
Pediatric Scoliosis Cohort
Pediatric patients under 18 years old who underwent posterior instrumented spinal fusion for scoliosis correction (idiopathic, neuromuscular, or congenital) between April 2023 and March 2026. This single cohort is evaluated retrospectively to identify risk factors for homologous blood transfusion and to assess the impact of intraoperative Cell Saver use
干预措施: Intraoperative Cell Saver Autologous Reinfusion (Device)
结局指标
主要结局
Proportion of patients requiring perioperative homologous Red Blood Cell (RBC) transfusion
时间窗: : From the start of surgery (anesthesia induction) up to postoperative day 3 (Day 0 to Day 3).
次要结局
- Blood conservation rate achieved by intraoperative autologous blood salvage(Intraoperative period (from skin incision to skin closure))
- Total volume of homologous Red Blood Cells (RBC) transfused.(From the start of surgery up to postoperative day 3 (Day 0 to Day 3).)
研究者
Mehdi Trifa
Professor
Tunis University